Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Former Takeda CEO Yasuchika Hasegawa Dies at 80
Yasuchika Hasegawa, the former president and CEO of Takeda Pharmaceutical who helped transform the Japanese drug maker into a global pharmaceutical player, died on July 3 at the age of 80, the company said on September 11. Hasegawa joined Takeda…
To read the full story
Related Article
- Takeda Advisor Hasegawa, Herald of Takeda Globalization, Steps Down
July 1, 2019
- Takeda Chairman Hasegawa Officially Steps Aside as Adviser
June 29, 2017
- Takeda Chairman Hasegawa to Retire, Become Adviser in June
April 14, 2017
- Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
BUSINESS
- LinDo Sets Sights on More Pediatric Deals as It Builds Drug-Loss Portfolio
October 6, 2026
- Shionogi to Buy IntraBio for US$2 Billion, Gains Rare Disease Drug
October 6, 2026
- Fujifilm AI Finds Potent New Inhibitors from Known Compound
October 6, 2026
- Boehringer’s Survodutide Makes Mark in Japan PIII Obesity Trial
October 6, 2026
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…